EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Tenecteplase for Acute Non–Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke

Gaoting Ma, Ran Mo, Yingting Zuo, Qingfeng Ma, Guangjian Zhao, Xiaoxi Yao, Ji Liang, Li Zhou, Yong He, Faqing Long, Zhengzhou Yuan, Lei Liu und 37 weitere

JAMA · 07.04.2026 · 335 (13) · 1137

DOI: 10.1001/jama.2026.0210 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift JAMA, erschienen am 07.04.2026. Verfasst von Gaoting Ma und 48 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders, Beijing, China. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Intracranial Hemorrhages, Ischemic Stroke, Tenecteplase. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The efficacy and safety of intravenous tenecteplase in non–large vessel occlusion acute ischemic stroke beyond 4.5 hours after symptom onset remain uncertain.

Objective

To assess the efficacy and safety of intravenous tenecteplase administered 4.5 to 24 hours after stroke onset in patients with non–large vessel occlusion and salvageable brain tissue. Design, Setting, and Participants This randomized, open-label, blinded end-point clinical trial was conducted at 48 centers in China. A total of 566 patients with non–large vessel occlusion stroke and evidence of potentially salvageable tissue determined on perfusion imaging presenting within 4.5 to 24 hours of the time last seen well were recruited between June 2, 2023, and August 4, 2025 (final follow-up, October 28, 2025).

Interventions

Patients were randomly assigned 1:1 using a minimization algorithm to receive intravenous tenecteplase (0.25 mg/kg; maximum dose, 25 mg; n = 282) or standard medical treatment (n = 284). Main Outcomes and Measures The primary efficacy outcome was an excellent functional outcome, defined as a score of 0 or 1 on the modified Rankin Scale at 90 days. Safety outcomes included symptomatic intracranial hemorrhage within 36 hours and mortality within 90 days.

Results

Among the 570 patients randomized, 566 were included in the primary analysis (median age, 68 [IQR, 59-75] years; 196 female [34.6%]). An excellent functional outcome was observed in 123 of 282 patients (43.6%) in the tenecteplase group and 97 of 284 (34.2%) in the control group (risk ratio, 1.28 [95% CI, 1.04-1.57]; P = .02). The incidence of symptomatic intracranial hemorrhage at 2.8% was higher with tenecteplase than with standard medical treatment at 0% (risk difference, 2.85% [95% CI, 1.16%-5.54%]; P = .004), and the mortality at 90 days was 5.0% and 3.2%, respectively (risk ratio, 1.57 [95% CI, 0.69-3.57]; P = .28). Conclusions and Relevance Among patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase administered 4.5 to 24 hours after onset resulted in a greater likelihood of an excellent functional outcome at 90 days than standard care but had an increased risk of symptomatic intracranial hemorrhage. Trial Registration ClinicalTrials.gov Identifier: NCT05752916

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrinolytic AgentsIntracranial HemorrhagesIschemic StrokeTenecteplaseAgedFemaleHumansMaleMiddle AgedAdministration, IntravenousTime FactorsTreatment OutcomeChinaTime-to-TreatmentIncidence

Substanzen

Fibrinolytic AgentsTenecteplase

Autor:innen und Institutionen

  • Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders, Beijing, China.
  • Stroke Center, Linyi People's Hospital, Linyi, China.
  • Department of Neurology, First People's Hospital of Chenzhou, First Clinical College of Xiangnan University, Chenzhou, China.
  • Department of Neurology, Changde Hospital, Xiangya School of Medicine, Central South University (First People's Hospital of Changde City), Changde, China.
  • Department of Neurology, Weifang People's Hospital, Weifang, China.
  • Department of Neurology, Liuyang Jili Hospital, Changsha, China.

Zitieren

APA

Ma, G., Mo, R., Zuo, Y., Ma, Q., Zhao, G., Yao, X., Liang, J., Zhou, L., He, Y., Long, F., Yuan, Z., Liu, L., Han, G., Tan, Y., Ai, Z., Cai, C., Liu, J., Zhang, L., Yang, H., …, & OPTION Investigators (2026). Tenecteplase for Acute Non–Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke. JAMA, 335(13), 1137. https://doi.org/10.1001/jama.2026.0210

Vancouver

Ma G, Mo R, Zuo Y, Ma Q, Zhao G, Yao X, et al. Tenecteplase for Acute Non–Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke. JAMA. 2026;335(13):1137. doi:10.1001/jama.2026.0210

BibTeX
@article{Ma2026,
  author = {Ma, Gaoting and Mo, Ran and Zuo, Yingting and Ma, Qingfeng and Zhao, Guangjian and Yao, Xiaoxi and Liang, Ji and Zhou, Li and He, Yong and Long, Faqing and Yuan, Zhengzhou and Liu, Lei and Han, Guosheng and Tan, Yan and Ai, Zhibing and Cai, Chunsheng and Liu, Juan and Zhang, Liyong and Yang, Haihua and Yi, Tingyu and Li, Li and Fu, Yao and Zhang, Yanxing and Shao, Xiangzhong and Yu, Zhipeng and Wu, Saizhen and Du, Yanqiu and Mao, Lingqun and Guo, Hongling and Chen, Xufeng and Chen, Yifei and Zhao, Qiong and Chi, Liyi and Liu, Yi and Zhang, Haochun and Li, Guangzong and Meng, Shujuan and Wu, Yifan and Wu, Jieying and Jiang, Ziying and Lei, Shaoyuan and Gao, Daiquan and Zhong, Lianmei and Fiehler, Jens and Wang, Duolao and Nguyen, Thanh N and Saver, Jeffrey L and Hao, Junwei and OPTION Investigators, OPTION Investigators},
  title = {Tenecteplase for Acute Non–Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {13},
  pages = {1137},
  doi = {10.1001/jama.2026.0210}
}
Kostenlos starten →